DOM-AT
Pharmaceutical compound
From Wikipedia, the free encyclopedia
DOM-AT, or DOMAT, also known as 5,8-dimethoxy-6-methyl-2-aminotetralin, is a cyclized phenethylamine and 2-aminotetralin related to the psychedelic amphetamine DOM.[1][2][3][4] It is specifically the cyclized 2-aminotetralin analogue of DOM.[2][3][4]
| Clinical data | |
|---|---|
| Other names | DOM/AT; DOMAT; 5,8-Dimethoxy-6-methyl-2-aminotetralin |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H19NO2 |
| Molar mass | 221.300 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The compound has been found to be a more potent agonist of peripheral serotonin receptors than DOM in vitro.[4][2][5] This activity was blocked by the serotonin receptor antagonist cinanserin and by the non-hallucinogenic serotonin receptor modulator 2-bromo-LSD (BOL-148).[2][5][3] However, DOM-AT was not tested for hallucinogen-type activity in animals or humans in these studies.[4] Subsequently, DOM-AT did not appear to show a typical hallucinogen-like profile in behavioral tests in rats (e.g., the conditioned avoidance response test).[2][6][3] In cats, DOM-AT produced a rage reaction, while in rabbits, it produced behavioral excitation and hyperthermia.[2][6] In later research, DOM-AT failed to substitute for LSD in rodent drug discrimination tests, whereas the related cyclized 2-aminoindan compound DOM-AI was effective, albeit with far lower potency than DOM (approximately 1/15th).[7] Based on these findings, DOM-AT has been deemed inactive in terms of hallucinogen-like activity and unlikely to be psychedelic in humans.[1][2]
DOM-AT was first described in the scientific literature by David E. Nichols in 1973.[3][8]
Other cyclized analogues of DOM and related psychedelics include DOM-CR, DMCPA, TFMBOX, jimscaline, TCB-2, LPH-5, and ZC-B.[1][4][2]